Comparative Pharmacology
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROCREAM.
METRO I.V. IN PLASTIC CONTAINER vs METROCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Topical, apply a thin film to affected area once or twice daily.
None Documented
None Documented
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)